rac-2-(4-((2-(ethylamino)-4-(trifluoromethyl)thiazol-5-yl)sulfonyl)phenyl)-1,1,1-trifluoropropan-2-ol

ID: ALA4283686

PubChem CID: 145992133

Max Phase: Preclinical

Molecular Formula: C15H16F6N2O3S2

Molecular Weight: 450.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCNC1=NC(C(F)(F)F)C(S(=O)(=O)c2ccc(C(C)(O)C(F)(F)F)cc2)S1

Standard InChI:  InChI=1S/C15H16F6N2O3S2/c1-3-22-12-23-10(14(16,17)18)11(27-12)28(25,26)9-6-4-8(5-7-9)13(2,24)15(19,20)21/h4-7,10-11,24H,3H2,1-2H3,(H,22,23)

Standard InChI Key:  DBUACKSDVHYFNR-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 28 29  0  0  0  0  0  0  0  0999 V2000
    6.1740   -6.1197    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5907   -6.8364    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.0030   -6.1172    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.3059   -7.2488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3048   -8.0762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0196   -8.4891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7360   -8.0757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7332   -7.2452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0178   -6.8361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0735   -7.4785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2533   -7.4379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9598   -8.2084    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6019   -8.7257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2922   -8.2748    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.8021   -6.7473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1746   -6.0112    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.9783   -6.7927    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.3103   -6.0773    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.5609   -9.5497    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.4512   -8.4871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4525   -9.3121    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.1650   -8.0735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1615   -8.8989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8801   -8.4849    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.1637   -7.2485    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.8740   -7.6531    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.8269   -9.9261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1338   -9.4786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  4  2  1  0
  2 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 10  1  0
 11 15  1  0
 15 16  1  0
 15 17  1  0
 15 18  1  0
 13 19  1  0
  7 20  1  0
 20 21  1  0
 20 22  1  0
 20 23  1  0
 22 24  1  0
 22 25  1  0
 22 26  1  0
 19 27  1  0
 27 28  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4283686

    ---

Associated Targets(Human)

GLRA3 Tchem Glycine receptor alpha-3/beta (286 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 450.43Molecular Weight (Monoisotopic): 450.0507AlogP: 3.20#Rotatable Bonds: 4
Polar Surface Area: 78.76Molecular Species: ACIDHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 3.86CX Basic pKa: 7.51CX LogP: 1.68CX LogD: -1.06
Aromatic Rings: 1Heavy Atoms: 28QED Weighted: 0.69Np Likeness Score: -0.69

References

1. Chakka N, Andrews KL, Berry LM, Bregman H, Gunaydin H, Huang L, Guzman-Perez A, Plant MH, Simard JR, Gingras J, DiMauro EF..  (2017)  Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators.,  137  [PMID:28575722] [10.1016/j.ejmech.2017.05.036]
2. Chakka N, Andrews KL, Berry LM, Bregman H, Gunaydin H, Huang L, Guzman-Perez A, Plant MH, Simard JR, Gingras J, DiMauro EF..  (2017)  Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators.,  137  [PMID:28575722] [10.1016/j.ejmech.2017.05.036]
3. Chakka N, Andrews KL, Berry LM, Bregman H, Gunaydin H, Huang L, Guzman-Perez A, Plant MH, Simard JR, Gingras J, DiMauro EF..  (2017)  Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators.,  137  [PMID:28575722] [10.1016/j.ejmech.2017.05.036]

Source